Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 7 , Pages 840-848, July 2007

Immediate-Release Methylphenidate for ADHD in Children With Comorbid Chronic Multiple Tic Disorder

Accepted 25 February 2007.

ABSTRACT 

Objective

To examine the safety and efficacy of immediate-release methylphenidate (MPH-IR) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children (ages 6-12 years) with Tourette's syndrome (96%) or chronic motor tic disorder (4%).

Method

Two cohorts of prepubertal children (N = 71) received placebo and three doses of MPH (0.1, 0.3, and 0.5 mg/kg) twice daily for 2 weeks each, under double-blind conditions as part of their involvement in a long-term observation study (1989-2004). Treatment effects were assessed with an extensive battery of parent-, teacher-, child-, and physician-completed rating scales and laboratory tasks.

Results

MPH-IR effectively suppressed ADHD, oppositional defiant disorder, and peer aggression behaviors. There was no evidence that MPH-IR altered the overall severity of tic disorder or obsessive-compulsive disorder behaviors. Teacher ratings indicated that MPH-IR therapy decreased tic frequency and severity.

Conclusions

MPH-IR appears to be a safe and effective short-term treatment for ADHD in the majority of children with chronic tic disorder; nevertheless, the possibility of tic exacerbation in susceptible individuals warrants careful monitoring of all patients.

Key Words:  attention-deficit/hyperactivity disorder , methylphenidate , aggression , chronic multiple tic disorder , Tourette's syndrome

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported in part by a research grant from the Tourette Syndrome Association, Inc., and P.H.S.grant no. MH45358 from the National Institute of Mental Health. The authors thank Dr. Joseph Schwartz for assisting with the data analyses, Linda Volkersz for conducting clinic evaluations, Michele and Michael De Angelis for providing pharmacy services, CIBA Pharmaceutical Company for supplying methylphenidate placebos, and three anonymous reviewers for suggesting helpful revisions. The authors are particularly indebted to the courageous families who made this study possible.Disclosure: The authors have no financial relationships to disclose.

PII: S0890-8567(09)62172-9

doi:10.1097/chi.0b013e31805c0860

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 7 , Pages 840-848, July 2007